Since no clinical trials have been developed for targeting IL13Rα2 in metastatic colorectal cancer, we propose a novel strategy based on blocking the IL-13/IL13Rα2 signalling axis with IL13Rα2 peptides to inhibit their prometastatic functions. Here, IL13RA2 is linked to metastatic colorectal cancer.